Camidge and Cetnar Revisit ASCO 2023 Data in Lung Cancer

Welcome to OncLive On Air^®! I’m your host today, Caroline Seymour.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode of ‘How This is Building Me,’ host D. Ross Camidge, MD, PhD, of the University of Colorado, is rejoined by Jeremy Paul Cetnar, MD, MSHPR, of Oregon Health and Science University, to discuss the good, the bad, and the ugly of the lung cancer data that were presented at the 2023 ASCO Annual Meeting.

Highlighted in the discussion include conversations around the use of adjuvant targeted therapy, tumor treating fields, and more.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air^®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive^® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.

*OncLive On Air^® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.